EP1575506A4 - Methods for improvement of lung function using tgf-beta inhibitors - Google Patents
Methods for improvement of lung function using tgf-beta inhibitorsInfo
- Publication number
- EP1575506A4 EP1575506A4 EP03771821A EP03771821A EP1575506A4 EP 1575506 A4 EP1575506 A4 EP 1575506A4 EP 03771821 A EP03771821 A EP 03771821A EP 03771821 A EP03771821 A EP 03771821A EP 1575506 A4 EP1575506 A4 EP 1575506A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- tgf
- improvement
- methods
- lung function
- beta inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39936902P | 2002-07-25 | 2002-07-25 | |
US399369P | 2002-07-25 | ||
PCT/US2003/023240 WO2004010929A2 (en) | 2002-07-25 | 2003-07-23 | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1575506A2 EP1575506A2 (en) | 2005-09-21 |
EP1575506A4 true EP1575506A4 (en) | 2008-04-23 |
Family
ID=31188573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03771821A Withdrawn EP1575506A4 (en) | 2002-07-25 | 2003-07-23 | Methods for improvement of lung function using tgf-beta inhibitors |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1575506A4 (en) |
AU (1) | AU2003256783A1 (en) |
CA (1) | CA2494367A1 (en) |
WO (1) | WO2004010929A2 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127575A1 (en) * | 2002-11-22 | 2004-07-01 | Feng Ying | Method for counteracting a pathologic change in the beta-adrenergic pathway |
ATE398125T1 (en) | 2003-03-12 | 2008-07-15 | Millennium Pharm Inc | QUINAZOLINE DERIVATIVES AS TGF BETA INHIBITORS |
NZ545913A (en) | 2003-09-19 | 2009-01-31 | Astrazeneca Ab | Quinazoline derivatives |
EP1899332A1 (en) | 2005-06-24 | 2008-03-19 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c. |
US8597646B2 (en) * | 2005-10-25 | 2013-12-03 | The Johns Hopkins University | Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders |
US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
DK2918288T3 (en) | 2006-10-03 | 2017-11-27 | Genzyme Corp | Use of TGF-beta antagonists in the treatment of infants at risk of developing bronchopulmonary dysplasia |
WO2008071605A2 (en) * | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
US8536187B2 (en) | 2008-07-03 | 2013-09-17 | Gilead Sciences, Inc. | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections |
EP2379076B1 (en) | 2008-12-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
CA2803665C (en) | 2010-06-28 | 2019-03-05 | Dieter Dorsch | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
AU2012224979B2 (en) | 2011-03-09 | 2017-01-19 | Merck Patent Gmbh | Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses |
WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
IN2014DN03049A (en) | 2011-10-26 | 2015-05-15 | Seattle Childrens Res Inst | |
TW201815787A (en) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
TW201813963A (en) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
TW201825465A (en) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
PT3691620T (en) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN108727282B (en) * | 2018-06-14 | 2021-03-02 | 温州医科大学附属第一医院 | Benzene sulfonyl amino-containing anti-inflammatory compound and synthesis method thereof |
CN108912061B (en) * | 2018-06-14 | 2021-03-19 | 温州医科大学 | Synthetic method of quinazoline inflammation inhibition compound |
CN108727283B (en) * | 2018-06-14 | 2021-03-02 | 温州医科大学附属第一医院 | Synthesis method of benzenesulfonyl amide anti-inflammatory compound |
CN108912059B (en) * | 2018-06-14 | 2021-03-02 | 温州医科大学附属第一医院 | Synthetic method of nitrogenous heterocyclic inflammation inhibiting compound |
CN108912060B (en) * | 2018-06-14 | 2021-03-19 | 温州医科大学 | Quinazoline anti-inflammatory compound and synthesis method thereof |
CN109053597B (en) * | 2018-06-14 | 2021-03-19 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Inflammation inhibiting compound and preparation method thereof |
WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
CN112568188B (en) * | 2021-02-24 | 2021-05-25 | 澎立生物医药技术(上海)有限公司 | Method for preparing Brown Norway rat pulmonary fibrosis model |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5439895A (en) * | 1992-07-15 | 1995-08-08 | Ono Pharmaceutical Co., Ltd. | 4-aminoquinazoline derivatives |
WO2000066631A1 (en) * | 1999-04-30 | 2000-11-09 | Cambridge Antibody Technology Limited | SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1? |
US6277989B1 (en) * | 1998-08-28 | 2001-08-21 | Scios, Inc. | Quinazoline derivatives as medicaments |
WO2001062756A1 (en) * | 2000-02-21 | 2001-08-30 | Smithkline Beecham P.L.C. | Pyridinylimidazoles |
WO2002022602A2 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Triazole compounds useful as protein kinase inhibitors |
WO2002040468A1 (en) * | 2000-11-16 | 2002-05-23 | Smithkline Beecham Corporation | Compounds |
WO2002047690A1 (en) * | 2000-12-12 | 2002-06-20 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2002062794A2 (en) * | 2001-02-02 | 2002-08-15 | Glaxo Group Limited | Compounds |
US20040038856A1 (en) * | 2002-05-17 | 2004-02-26 | Sarvajit Chakravarty | Treatment of fibroproliferative disorders using TGF-beta inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4366189A (en) * | 1979-12-21 | 1982-12-28 | Ciba-Geigy Corporation | 4-Heterocyclyl-4'-vinylstilbenes |
US20040127575A1 (en) * | 2002-11-22 | 2004-07-01 | Feng Ying | Method for counteracting a pathologic change in the beta-adrenergic pathway |
-
2003
- 2003-07-23 WO PCT/US2003/023240 patent/WO2004010929A2/en active Search and Examination
- 2003-07-23 CA CA002494367A patent/CA2494367A1/en not_active Abandoned
- 2003-07-23 AU AU2003256783A patent/AU2003256783A1/en not_active Abandoned
- 2003-07-23 EP EP03771821A patent/EP1575506A4/en not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5439895A (en) * | 1992-07-15 | 1995-08-08 | Ono Pharmaceutical Co., Ltd. | 4-aminoquinazoline derivatives |
US6277989B1 (en) * | 1998-08-28 | 2001-08-21 | Scios, Inc. | Quinazoline derivatives as medicaments |
WO2000066631A1 (en) * | 1999-04-30 | 2000-11-09 | Cambridge Antibody Technology Limited | SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1? |
WO2001062756A1 (en) * | 2000-02-21 | 2001-08-30 | Smithkline Beecham P.L.C. | Pyridinylimidazoles |
WO2002022602A2 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Triazole compounds useful as protein kinase inhibitors |
WO2002040468A1 (en) * | 2000-11-16 | 2002-05-23 | Smithkline Beecham Corporation | Compounds |
WO2002047690A1 (en) * | 2000-12-12 | 2002-06-20 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2002062794A2 (en) * | 2001-02-02 | 2002-08-15 | Glaxo Group Limited | Compounds |
US20040038856A1 (en) * | 2002-05-17 | 2004-02-26 | Sarvajit Chakravarty | Treatment of fibroproliferative disorders using TGF-beta inhibitors |
Non-Patent Citations (1)
Title |
---|
DE BOER WILLEM I ET AL: "Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 158, no. 6, December 1998 (1998-12-01), pages 1951 - 1957, XP002343270, ISSN: 1073-449X * |
Also Published As
Publication number | Publication date |
---|---|
WO2004010929A3 (en) | 2005-12-01 |
CA2494367A1 (en) | 2004-02-05 |
EP1575506A2 (en) | 2005-09-21 |
AU2003256783A1 (en) | 2004-02-16 |
WO2004010929A2 (en) | 2004-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1575506A4 (en) | Methods for improvement of lung function using tgf-beta inhibitors | |
EG25482A (en) | Inhibitors | |
HK1077762A1 (en) | INHIBITORS OF TFGβ | |
TWI369354B (en) | Cytokine inhibitors | |
IL174010A0 (en) | Cytokine inhibitors | |
GB0325192D0 (en) | Method of use | |
AU2003202263A1 (en) | Roh-kinase inhibitors | |
EP1667982A4 (en) | Isoquinolinone potassium channel inhibitors | |
AU2003207881A1 (en) | Dipeptidyl peptidase inhibitors | |
EP1667683A4 (en) | Quinoline potassium channel inhibitors | |
EP1667978A4 (en) | Isoquinolinone potassium channel inhibitors | |
EP1569633A4 (en) | Ca ix-specific inhibitors | |
EP1532133A4 (en) | Nf-:b inhibitors | |
IL165475A0 (en) | Nitrooxyderivatives of eyclooxygenase-2 inhibitors | |
EP1667977A4 (en) | Isoquinolinone potassium channel inhibitors | |
ZA200707086B (en) | Cytokine inhibitors | |
ZA200409686B (en) | Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors | |
IL164898A0 (en) | Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors | |
EP1667973A4 (en) | Quinoline potassium channel inhibitors | |
EP1570847A4 (en) | Phosphodiesterase 10a inhibitors | |
AU2003215635A1 (en) | Thiazol-2-yl-imine compounds as pde-7 inhibitors | |
GB0311195D0 (en) | Glyoxalase inhibitors | |
AU2003213107A8 (en) | Methods for analysis of molecular events | |
AU2003232362A8 (en) | 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors | |
TW576286U (en) | Nail-absence non-percussion device for nailing gun |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050214 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 239/00 19850101ALI20051208BHEP Ipc: A61K 31/435 19850101ALI20051208BHEP Ipc: A61K 31/53 19850101AFI20051208BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080328 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 11/06 20060101ALI20080320BHEP Ipc: A61P 11/00 20060101ALI20080320BHEP Ipc: C07D 239/00 20060101ALI20080320BHEP Ipc: A61K 31/435 20060101ALI20080320BHEP Ipc: A61K 31/53 20060101ALI20080320BHEP Ipc: A61K 31/4985 20060101ALI20080320BHEP Ipc: A61K 31/498 20060101ALI20080320BHEP Ipc: A61K 31/505 20060101ALI20080320BHEP Ipc: A61K 31/00 20060101AFI20080320BHEP |
|
17Q | First examination report despatched |
Effective date: 20090402 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20091013 |